Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

NCT06691035 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Metastatic Breast Cancer
HER2-negative Breast Cancer

Interventions

DRUG: Elacestrant
BIOLOGICAL: DC1 native/mutated ESR1

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]